[go: up one dir, main page]

WO2001031342A3 - DIAGNOSTIC ET TRAITEMENT DU CANCER UTILISANT DES POLYPEPTIDES ET DES POLYNUCLEOTIDES StAR - Google Patents

DIAGNOSTIC ET TRAITEMENT DU CANCER UTILISANT DES POLYPEPTIDES ET DES POLYNUCLEOTIDES StAR Download PDF

Info

Publication number
WO2001031342A3
WO2001031342A3 PCT/US2000/029556 US0029556W WO0131342A3 WO 2001031342 A3 WO2001031342 A3 WO 2001031342A3 US 0029556 W US0029556 W US 0029556W WO 0131342 A3 WO0131342 A3 WO 0131342A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
star
polynucleotides
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/029556
Other languages
English (en)
Other versions
WO2001031342A2 (fr
Inventor
Scott Powers
Allyson Servoss
Rong Wendy Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Priority to AU14394/01A priority Critical patent/AU1439401A/en
Publication of WO2001031342A2 publication Critical patent/WO2001031342A2/fr
Publication of WO2001031342A3 publication Critical patent/WO2001031342A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes, des réactifs et des kits destinés au diagnostic et au traitement du cancer chez les mammifères, et notamment chez l'homme. L'invention repose sur l'étonnante découverte que le gène StAR est surexprimé et/ou amplifié dans plusieurs types de cellules cancéreuses. Ainsi, on peut utiliser les procédés de l'invention dans la détection du cancer ou d'une propension à développer le cancer, dans le suivi de l'efficacité d'un traitement anticancéreux et dans le traitement des cancers, notamment par l'inhibition de l'expression et/ou de l'activité du gène StAR dans une cellule cancéreuse.
PCT/US2000/029556 1999-10-26 2000-10-26 DIAGNOSTIC ET TRAITEMENT DU CANCER UTILISANT DES POLYPEPTIDES ET DES POLYNUCLEOTIDES StAR Ceased WO2001031342A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14394/01A AU1439401A (en) 1999-10-26 2000-10-26 Diagnosis and treatment of cancer using star polypeptides and polynucleotides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16168799P 1999-10-26 1999-10-26
US60/161,687 1999-10-26
US16755699P 1999-11-23 1999-11-23
US60/167,556 1999-11-23
US69673300A 2000-10-25 2000-10-25
US09/696,733 2000-10-25

Publications (2)

Publication Number Publication Date
WO2001031342A2 WO2001031342A2 (fr) 2001-05-03
WO2001031342A3 true WO2001031342A3 (fr) 2002-01-24

Family

ID=27388658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029556 Ceased WO2001031342A2 (fr) 1999-10-26 2000-10-26 DIAGNOSTIC ET TRAITEMENT DU CANCER UTILISANT DES POLYPEPTIDES ET DES POLYNUCLEOTIDES StAR

Country Status (2)

Country Link
AU (1) AU1439401A (fr)
WO (1) WO2001031342A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10251028A1 (de) * 2002-11-01 2004-05-19 Jenapharm Gmbh & Co. Kg Verwendung von Progesteron oder einem Progesteronrezeptor-Agonisten zur Hemmung der Steroidsynthese
WO2018195273A1 (fr) * 2017-04-19 2018-10-25 The Corporation Of Mercer University Protéine sam-1, composition et méthodes d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066728A1 (fr) * 1999-05-03 2000-11-09 Compugen Ltd. Homologues de star

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066728A1 (fr) * 1999-05-03 2000-11-09 Compugen Ltd. Homologues de star

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU J ET AL: "Expression of the steroidogenic acute regulatory protein mRNA in adrenal tumors and cultured adrenal cells.", JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 1, 1996, pages 43 - 50, XP001003088, ISSN: 0022-0795 *
MOOG-LUTZ CHRISTEL ET AL: "MLN64 exhibits homology with the steroidogenic acute regulatory protein (StAR) and is over-expressed in human breast carcinomas.", INTERNATIONAL JOURNAL OF CANCER, vol. 71, no. 2, 1997, pages 183 - 191, XP001004431, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
WO2001031342A2 (fr) 2001-05-03
AU1439401A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
Fleming et al. Human NEIL3 gene expression regulated by epigenetic-like oxidative DNA modification
Kievit Follow-up of patients with colorectal cancer: numbers needed to test and treat
AU2003260966A1 (en) Genes and polypeptides relating to human pancreatic cancers
WO2002090925A3 (fr) Polypeptides acides nucleiques associes au cancer
TW200512298A (en) Method of diagnosing breast cancer
WO2005040758A3 (fr) Utilisation de pirfenidone dans des posologies therapeutiques
WO2002059373A3 (fr) Genes surexprimes dans des maladies de la prostate servant de cibles diagnostiques et therapeutiques
WO2001072962A3 (fr) Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique
CA2296535A1 (fr) Inhibition du gene ras a l'aide d'oligonucleotides antisens
WO2001034802A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer de la prostate
WO2007143752A3 (fr) Cibles pour le pronostic ou la thérapie dans le cancer du sein
WO2006074367A3 (fr) Procede permettant de predire et de reduire le risque de metastases du cancer du sein dans les poumons
WO2002059611A3 (fr) Diagnostic et traitement du cancer a l'aide de polypeptides et de polynucleotides pellino de mammifere
Radunović et al. Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex
WO2000018961A3 (fr) Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
AU2003264078A1 (en) Method for analyzing body fluids for the presence of cancer cells, use thereof, corresponding analysis kits, and use of specific active substances for treating cancer
WO2003030725A3 (fr) Diagnostic et therapies d'un cancer du pancreas
WO2004005530A3 (fr) Compositions et techniques de traitement et de detection de cancers multiples
WO2001065998A3 (fr) Methodes de diagnostic et de traitement du cancer du sein
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2001031342A3 (fr) DIAGNOSTIC ET TRAITEMENT DU CANCER UTILISANT DES POLYPEPTIDES ET DES POLYNUCLEOTIDES StAR
WO2004009112A8 (fr) Utilisation d'urease pour inhiber la croissance de cellules cancereuses
WO2005085863A3 (fr) Correlation entre biomarqueurs et composes dans le diagnostic et le traitement du cancer
WO2003098223A3 (fr) Nouvelles therapies et procedes de criblage de composes therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP